Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
1. VIBRANT trial met its primary endpoint with significant NPS reduction. 2. Verekitug shows promise with a well-tolerated safety profile. 3. Key secondary endpoints also reported significant improvements. 4. Verekitug may address substantial unmet needs in CRSwNP. 5. Upcoming asthma trial results may further enhance Verekitug's prospects.